Clinical Trial Update: Clinical Study of PAL-222 Targeting Patients With Myopic Chorioretinal Atrophy (PAMyCA) [NA]

View source ↗

Summary

A clinical study of PAL-222 for myopic chorioretinal atrophy is ongoing, with status listed as ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myopic Chorioretinal Atrophy

Drugs mentioned

• PAL-222

Snippet

Sponsor: PharmaBio Corporation | Conditions: Myopic Chorioretinal Atrophy | NA | Status: ACTIVE_NOT_RECRUITING